Here are relevant reports on : human-microbiome-market
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Digital Identity Solutions Market by Hardware (RFID Reader & Encoder, Hardware-Based Tokens, Processor ID Cards), Solution type (Identity Verification, Authentication), Identity Type (Non-Human Identity (NHI), Human Identity) - Global Forecast to 2031
The global digital identity solutions market is expected to grow from USD 44.20 billion in 2025 to USD 132.14 billion by 2031, at a compound annual growth rate (CAGR) of 20.0% during the forecast period. The Key Players Thales (France), NEC (Japan), IDEMIA (France), Samsung SDS (South Korea), TELUS (US), HID Global (US), CrowdStrike (US), DXC Technology (US), IBM (US), CyberArk (US), and HCLTech (US).
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
Europe Identity and Access Management (IAM) Market by Technology [Access Management, Identity Governance & Administration (IGA), Privileged Access Management (PAM)], Type (Workforce, CIAM, B2B), Identity Type (Human, Non-Human Identity) - Forecast to 2030
The size of the identity and access management (IAM) market in Europe is projected to grow from USD 6.09 billion in 2025 to USD 9.79 billion by 2030 at a CAGR of 10.0% during the forecast period. The Key Players Microsoft (US), Thales (France), Evidian (France), Ping Identity (US), IBM (US), Okta (US), Oracle (US), iC Consult (Germany), IN Groupe (France), Ubisecure (Finland), CyberArk (US), HID Global (US), Authentik (US), cidaas (Germany), Curity (Sweden), Traxion (Netherlands), Elimity (Belgium), and Omada (Denmark)
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
US Identity and Access Management (IAM) Market by Technology [Access Management, Identity Governance & Administration (IGA), Privileged Access Management (PAM)], Type [Workforce, CIAM, 82B], Identity Type [Human, Non-human]-Forecast to 2030
The identity and access management (IAM) market in the US is expected to expand significantly, rising from USD 7.34 billion in 2025 to USD 11.09 billion by 2030 at a CAGR of 8.6%. The key players include Microsoft (US), Ping Identity (US), IBM (US), Okta (US), Oracle (US), SailPoint (US), Saviynt (US), CyberArk (US), Akamai Technologies (US), Entrust (US), RSA Security (US), Avatier (US), ManageEngine (US), SecureAuth (US), EmpowerID (US), Simeio (US), One Identity (US), FusionAuth (US), Auth0 (US), and Zuora (US).
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome Sequencing), Technology (Sequencing by Synthesis, Nanopore Sequencing), End User - Global Forecast to 2028
The global microbiome sequencing services market, valued at US$250 million in 2022, stood at US$284 million in 2023 and is projected to advance at a resilient CAGR of 14.3% from 2023 to 2028, culminating in a forecasted valuation of US$555 billion by the end of the period. Growth in this market is primarily driven by the increasing demand for metagenomic sequencing, the growing focus on the development of human microbiome therapeutics, and the high cost of advanced sequencing infrastructure.
- Published: May 2023
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
